Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Yarrow BioscienceYARW -2.78%13 EV-to-OCF is -7.95 as of Sep. 15, 2026. GuruFocus rates YARW with a GF Score™ of 13/100. Among 1,405 Biotechnology companies, Yarrow Bioscience ranks better than 65.62% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Yarrow Bioscience's Enterprise Value is $47.18 Mil.
Yarrow Bioscience's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-5.93 Mil. Therefore, Yarrow Bioscience's EV-to-OCF for today is -7.95.
The historical rank and industry rank for Yarrow Bioscience's EV-to-OCF or its related term are showing as below:
YARW'
s EV-to-OCF Range Over the Past 10 Years
Min: -8.78 Med: 0 Max: 0
Current: -7.95
YARW's EV-to-OCF is ranked better than 65.62% of 1405
companies
in the Biotechnology industry
Industry Median: -3.38
vs YARW: -7.95
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Yarrow Bioscience's PE Ratio (TTM) for today is calculated as:
Yarrow Bioscience's share price for today is $26.22.
Yarrow Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-27.379.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Yarrow Bioscience EV-to-OCF Related Terms
Yarrow Bioscience EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Yarrow Bioscience's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yarrow Bioscience EV-to-OCF Chart
Yarrow Bioscience Annual Data
Trend
Dec25
EV-to-OCF
0.00
Yarrow Bioscience Quarterly Data
Jun25
Dec25
Mar26
Jun26
EV-to-OCF
0.00
0.00
0.00
0.00
YARW vs CGTX, RANI, VRCA: EV-to-OCF Comparison
For the Biotechnology subindustry, Yarrow Bioscience's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yarrow Bioscience EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Yarrow Bioscience's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Yarrow Bioscience's EV-to-OCF falls into.
Yarrow Bioscience's current Enterprise Value is $47.18 Mil.
Yarrow Bioscience's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.93 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yarrow Bioscience (YARW) has a EV-to-OCF of -7.95 as of Sep. 15, 2026. According to the industry distribution chart, Yarrow Bioscience ranks #483 out of 1405 companies in the Biotechnology industry, placing it in the top 34.4%.
Is Yarrow Bioscience's EV-to-OCF too high?
Yarrow Bioscience's current EV-to-OCF is -7.95. Based on the distribution chart, Yarrow Bioscience ranks #483 out of 1405 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Yarrow Bioscience has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Yarrow Bioscience's EV-to-OCF compare to CGTX and RANI?
According to the Biotechnology industry distribution chart, Yarrow Bioscience ranks #483 out of 1405 companies for EV-to-OCF. This puts Yarrow Bioscience in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Yarrow Bioscience's current EV-to-OCF is -7.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yarrow Bioscience stock overvalued right now?
Yarrow Bioscience (YARW) has a current EV-to-OCF of -7.95. The current EV-to-OCF is -7.95. Yarrow Bioscience's overall GF Score™ is 13/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Yarrow Bioscience (YARW), the current EV-to-OCF is -7.95 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
13GF Score
Get the complete analysis for YARW
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
YARW has been successfully added to your 
